Zoetis Inc. (NYSE:ZTS) Position Boosted by Rockline Wealth Management LLC

Rockline Wealth Management LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,823 shares of the company’s stock after purchasing an additional 252 shares during the period. Rockline Wealth Management LLC’s holdings in Zoetis were worth $949,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Pensionfund Sabic raised its position in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares during the period. PFW Advisors LLC purchased a new stake in Zoetis during the fourth quarter valued at about $1,764,000. JPMorgan Chase & Co. boosted its holdings in shares of Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the period. Simplify Asset Management Inc. purchased a new position in shares of Zoetis in the third quarter worth approximately $11,684,000. Finally, Nordea Investment Management AB lifted its position in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after acquiring an additional 572,511 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

ZTS opened at $171.93 on Tuesday. The stock has a 50-day moving average of $169.62 and a 200-day moving average of $179.44. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a market cap of $77.57 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the company posted $1.36 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, equities research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.16%. Zoetis’s payout ratio is currently 37.59%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent analyst reports. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley dropped their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.